en · de · es · pt
handling-notes.peptides9000.com › Blog › Melanocortin Receptor Agonist Pharmacology — Common Mistakes

Melanocortin Receptor Agonist Pharmacology — Common Mistakes

By Editorial Desk · published 2025-07-18 · last reviewed 2025-09-08 · Blog

MC4R raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

This page was last updated on 2025-09-08 and is reviewed periodically as new material appears.

Melanocortin Receptor Agonist Pharmacology

Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.

Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.

Identity and Chemical Background

PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.

Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.

Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.

Pt-141 at a glance

PropertyValueNotes
Molecular classCyclic heptapeptideMelanocortin receptor agonist
Molecular weightApproximately 1025 DaCalculated from the peptide sequence
AppearanceWhite to off-white powderCommon for lyophilized peptide preparations
SolubilitySoluble in waterAlso soluble in polar organic solvents
Storage temperature-20 °C or belowUsed for long-term retention

Bremelanotide Identity and Background

The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.

Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.

Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.

Related pages on this site

Bremelanotide Background And Development

Bremelanotide is a synthetic cyclic heptapeptide that acts on a family of G-protein-coupled receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide associated with pigmentation and several central signalling pathways. A lactam bridge constrains the ring and slows enzymatic breakdown, which distinguishes it from the linear parent molecule. Research interest moved over time from pigment biology toward central nervous system effects, particularly circuits connected to sexual desire. Parenteral delivery is used because oral bioavailability is poor.

Early clinical work used an intranasal formulation, and later programmes switched to subcutaneous delivery for more consistent absorption. A subcutaneous product received regulatory approval in the United States in 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Approval followed phase 3 trials in which active treatment separated from placebo on desire and distress measures, though the average difference was modest. Labeling carries a caution about transient blood pressure elevation, so cardiovascular history is assessed before prescribing. Questions about durability of benefit beyond several months remain open.

Published discussion sits at the intersection of peptide chemistry, neuroendocrinology and sexual medicine. Trial reports emphasise change scores on validated instruments, while mechanistic papers focus on hypothalamic circuits and receptor selectivity. Because placebo response in this field is large, effect sizes are usually reported with confidence intervals rather than as isolated averages. Reviews note that female and male data sets are not interchangeable and should be read separately. Diagnostic terminology has been revised over time, which complicates comparison between older and newer studies.

Background from the literature

=== Industrial synthesis === Glutamic acid is produced on the largest scale of any amino acid, with an estimated annual production of about 1.5 million tons in 2006. Chemical synthesis was supplanted by the aerobic fermentation of sugars and ammonia in the 1950s, with the organism Corynebacterium glutamicum (also known as Brevibacterium flavum) being the most widely used for production. Isolation and purification can be achieved by concentration and crystallization; it is also widely available as its hydrochloride salt.

I reject only the concept that black liberation can be achieved through the leadership of white liberals." He added that "the [white] liberal is no enemy, he's a friend – but for the moment he holds us back, offering a formula too gentle, too inadequate for our struggle". Biko's approach to activism focused on psychological empowerment, and both he and the BCM saw their main purpose as combating the feeling of inferiority that most black South Africans experienced. Biko expressed dismay at how "the black man has become a shell, a shadow of man ... bearing the yoke of oppression with sheepish timidity", and stated that "the most potent weapon in the hands of the oppressor is the mind of the oppressed". He believed that blacks needed to affirm their own humanity by overcoming their fears and believing themselves worthy of freedom and its attendant responsibilities. He defined Black Consciousness as "an inward-looking process" that would "infuse people with pride and dignity". To promote this, the BCM adopted the slogan "Black is Beautiful". One of the ways that Biko and the BCM sought to achieve psychological empowerment was through community development. Community projects were seen not only as a way to alleviate poverty in black communities but also as a means of transforming society psychologically, culturally, and economically. They would also help students to learn about the "daily struggles" of ordinary black people and to spread Black Consciousness ideas among the population.

== Contraindication for specific diseases == Aminoglycosides can exacerbate weakness in patients with myasthenia gravis, and use is therefore avoided in these patients. Aminoglycosides are contraindicated in patients with mitochondrial diseases as they may result in impaired mtDNA translation, which can lead to irreversible hearing loss, tinnitus, cardiac toxicity, and renal toxicity. However, hearing loss and tinnitus have also been observed in some patients without mitochondrial diseases.

Sources: en.wikipedia.org

Further detail

"You have no idea what the Tour de France is," Henri said. "It's a Calvary. Worse than that, because the road to the Cross has only 14 stations and ours has 15. We suffer from the start to the end. You want to know how we keep going? Here..." He pulled a phial from his bag. "That's cocaine, for our eyes. This is chloroform, for our gums." "This," Ville said, emptying his shoulder bag "is liniment to put warmth back into our knees." "And pills. Do you want to see pills? Have a look, here are the pills." Each pulled out three boxes. "The truth is," Francis said, "that we keep going on dynamite." Henri spoke of being as white as shrouds once the dirt of the day had been washed off, then of their bodies being drained by diarrhea, before continuing:

=== Arrangements === According to the visit schedule announced by the White House, Xi Jinping and his wife Peng Liyuan would arrive at Andrews Air Force Base on September 23. Trump and First Lady Melania Trump would greet the couple at the airport and held a welcoming ceremony. On September 24, the Trump couple would greet Xi and Peng at the White House, followed by a guard of honor review in the Rose Garden before the summit meeting. That evening, a state dinner would be held in the East Room of the White House, which will be attended by several heads of American technology giants. On September 25, the Trump couple would host a tea party for Xi and Peng at the White House, and the two sides would then visit to the National Archives of the United States to see founding documents of the United States. After the trip, Xi and Peng would return to Andrews Air Force Base and leave the United States by special plane. The guest list for the state dinner included:

=== Organic reactions === Hydrogen peroxide is frequently used as an oxidizing agent. Illustrative is oxidation of thioethers to form sulfoxides, such as conversion of thioanisole to methyl phenyl sulfoxide:

And while many studies have discussed and illustrated the immunosuppressive effects of CGB on T-cell proliferation, others have shown a contradictory trophic effect, further deepening the notion of an immunosuppressive pregnancy environment brought on by CGB. CGB encourages trophoblast invasion and interstitial theca cell proliferation through the overmodulation of extracellular-regulated kinase (ERK) and AKT signals, and the instigation of leptin production by CGB requires a dialogue between cAMP and p38 signaling pathways in the syncytiotrophoblast. It has also been shown that CGB has a positive impact on the proliferation of CD4+25+ T cells and that it attracts these cells to the endometrium in early pregnancy. Immune cells located at the implantation site actively contribute to embryo implantation. And so, through the modulation of inflammatory-promoting Th1 cells and anti-inflammatory Th2 cells, CGB plays a critically important role in the successful implantation of the embryo to the endometrial wall.

Sources: en.wikipedia.org

Frequently asked questions

What is PT-141?

PT-141 is the research code for bremelanotide, a cyclic peptide developed as a melanocortin receptor agonist. The code has appeared in literature and catalog listings since early development. Bremelanotide is the international nonproprietary name.

How does its mechanism differ from PDE5 inhibitors?

PDE5 inhibitors act on peripheral vascular tissue to increase blood flow. Bremelanotide acts centrally on melanocortin receptors and is associated with dopaminergic pathways. The two approaches therefore target different parts of the arousal response.

Is bremelanotide a hormone?

It is a synthetic peptide analog rather than a hormone produced by the body. Alpha-melanocyte-stimulating hormone is the natural peptide it resembles. The two share structural features but are distinct molecules.

What is PT-141?

PT-141 is a laboratory code for bremelanotide, a synthetic peptide that activates melanocortin receptors. It has been developed both as an injectable pharmaceutical product and as a research chemical. The two contexts differ sharply in how identity, purity, and dosing are controlled.

Network